We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BeiGene Vows to Fight Bristol Myers Squibb’s Abraxane Contract Pull-Out
BeiGene Vows to Fight Bristol Myers Squibb’s Abraxane Contract Pull-Out
Chinese biopharmaceutical company BeiGene is refusing to dissolve its Abraxane cancer drug deal with Bristol Myers Squibb (BMS), saying that the U.S. company’s proposed pull-out deal is just an attempt to stem potential arbitration costs, according to a new filing with the Securities and Exchange Commission (SEC).